ASCO Journal Club   

Journal Club Q&A done in partnership with ASCO the Journal of Clinical Oncology

Questions discussed in this category



Are there specific patient populations in which you may feel comfortable with a patient selecting only one adjuvant therapy approach (tamoxifen vs RT)...

What factors do you consider? Is your thought process at all different from your approach to boost with IDC?  Do you apply TROG 7.01 data (age ...

What resection margins are required for pure DCIS with adjuvant RT?  What resection margins are required for pure DCIS without RT? 

What advantages/disadvantages are there between assays or over traditional clinical pathologic factors? What other concerns do you have?

Should patients with moderate penetrance pathogenic variants be managed similar to BRCA patients and consider risk reducing contralateral mastectomy?&...

Genes such as ATM, CHEK2, PALB2, RAD51C/D, BRIP1 seem to show some potential increased risk of ovarian cancer. Should these patients under prophylacti...

What about a higher penetrance PV such as PALB2? See JCO OGR 8/2021 by @Mark E. Robson discussing management of non-BRCA pathogenic va...

In a scenario where patient's other clinical/familial risk does not sufficiently qualify them? See JCO OGR 8/2021 by @Mark E. Robson discussing manag...

We sometimes find highly suspicious LNs by CT, PET or MRI in the undissected regional lymphatics, and surgeons may not be willing to perform another o...

Data from the SOFT/TEXT trials showed clinical benefit in ovarian suppression + aromatase inhibition for high risk, premenopausal ...

Do you worry about the ability to collect stem cells (at the time of progression to MM) if someone with SMM has been on prolonged lenalidomide?

Would you be more or less likely to use a cisplatin-containing regimen if a patient had previously responded to chemoradiation with concurrent cisplat...

Should this be done at the time of recurrence or after failure of 1st line therapy for recurrence?

There are now five PD-1/PDL-1 inhibitors approved for metastatic bladder CA, one (Atezolizumab) as first-line therapy in cisplatin-ineligible patients...

Can you extrapolate the data on Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma to patients on a...

In this study, doses of 2mg/kg Q3wks, 10mg/kg Q3wks and 10mg/kg Q2wks were used. What did the majority of these patients in CR receive? 

Are you using ctDNA blood tests for targetable mutations at the time of diagnosis, at the time of disease progression, or not at all?

Alternatively, would a biopsy of a metastatic bone lesion be preferred in a patient who has already progressed on chemo and hormonal therapy?

Given the FDA breakthrough therapy designation for olaparib in BRCA1/2 and ATM mutated mCRPC, when do you sequence mCRPC? Do you have a preferred...

Based on 2-3% MSH2 mutation and 1% MLH1 mutation rates in metastatic disease regardless of castration sensitivity, should we be looking for this earli...


Papers discussed in this category


JCO Precision Oncology, 2017 Sep 29

Sci Rep, 2014 Sep 09

Medicine (Baltimore),

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-01

JCO Precision Oncology, 2017 May 31

The New England journal of medicine, 2016-08-04

J. Clin. Oncol., 2018-07-01

J. Clin. Oncol., 2019 Oct 16

Lancet (London, England), 2017-01-07

The New England journal of medicine, 2017-03-16

J. Clin. Oncol., 2018-06-10

Nature medicine, 2017-06

Oncotarget, 2016-08-16

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10

JAMA Oncol, 2016 Mar

N. Engl. J. Med.,

Clin Oncol (R Coll Radiol), 2016-12-01

The New England journal of medicine, 2009-05-14

Ann. Oncol., 2009-02-01

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-10-01

J. Clin. Oncol., 2011 Nov 21

Oncotarget,

Nature, 2017-04-26

Cancer discovery, 2017-12

Cancer discovery, 2016-10

J Clin Oncol, 2020 Oct 29

Semin Cell Dev Biol, 2011 Jul 28

Nat Med, 2019 Sep 30

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-03-01

Cancers (Basel), 2021 Dec 03

J Clin Oncol, 2021 Aug 18

J. Clin. Oncol., 2018-06-10

Lancet (London, England), 2017-10-21

The Lancet. Oncology, 2016-11

The New England journal of medicine, 2017-10-05

Nature, 2013-07-11

The New England journal of medicine, 2015-10-29

The New England journal of medicine, 2018-07-12

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-12-15

The New England journal of medicine, 2011-12-29

The New England journal of medicine, 2006-01-05

Lancet Oncol, 2013 Sep

N Engl J Med, 2011 Dec 29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-01

J. Clin. Oncol., 2019 Apr 19

N Engl J Med, 2016 Feb 25

The New England journal of medicine, 2018-12-27

Journal of the National Cancer Institute, 2011-03-16

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-11-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10

J Immunother Cancer, 2019 Aug 22

Journal for immunotherapy of cancer, 2017-11-21

Cancer management and research, 2017

Blood cancer journal, 2018-06-12

J. Clin. Oncol., 2013 Oct 21

Leukemia, 2013-08

J. Clin. Oncol., 2019 Oct 25

Leuk. Lymphoma, 2011 Feb 08

Cancer,

Leukemia, 2009-10

J. Clin. Oncol., 2021 Aug 10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-05-10

J. Clin. Oncol., 2014 Feb 10

J. Clin. Oncol., 2016-11-20

Ann. Surg.,

Ann Surg, 2019 Jan

Anticancer Res,

Cancer, 2018-04-01

Lancet Oncol., 2015-03-01

Radiother Oncol, 2021 Jan

Lancet Oncol, 2010 Dec 07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-04-20

Lancet (London, England), 2016-02-27